---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-22-000108"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T21:07:12.522234+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Exelixis Q3 revenue $411.7M; cabozantinib franchise up 39% YoY; GAAP EPS $0.23

## Summary
- Total revenues $411.7M (up 25% YoY); cabozantinib net product revenue $366.5M (+39% YoY).
- GAAP net income $73.2M ($0.23 diluted EPS) vs $38.2M ($0.12) prior year; non-GAAP EPS $0.31.
- Announced option deals with Cybrexa and Sairopa to access early-stage oncology assets.
- Cash and investments $2.1B at quarter end, up from $1.9B at Dec 2021.
- R&D expenses $198.8M (up from $163.4M); SG&A $115.0M (up from $101.6M).

## SEC filing metadata
- accession: 0000939767-22-000108
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976722000108/0000939767-22-000108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976722000108/exel-20221101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-22-000108
- JSON: https://secwatch.observer/filing/0000939767-22-000108.json
- Plain text: https://secwatch.observer/filing/0000939767-22-000108.txt

## Key facts
- Earnings Releases
  EXELIXIS, INC. reported the quarter ended September 30, 2022 results: revenue $411.7 million, net income $73.2 million, EPS $0.23.
  - Period: the quarter ended September 30, 2022
  - Revenue: $411.7 million
  - Net income: $73.2 million
  - EPS: $0.23
  - Result: reported results
  source text: EXELIXIS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $411.7 million, Cabozantinib Franchise Revenues of $366.5 million - - GAAP Diluted EPS of $0.23, Non-GAAP Diluted EPS of $0.31 -
  evidence_url: https://www.sec.gov/Archives/edgar/data/939767/000093976722000108/0000939767-22-000108-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.